READDI, Inc.
READDI is a nonprofit biotechnology company dedicated to proactively developing safe and effective broad-spectrum antiviral drugs before the next pandemic. It aims to prevent global health crises by leveraging academia, industry, and government expertise to discover and develop medicines that can be deployed immediately at the onset of future pandemics. READDI's mission is to ensure that broad-spectrum small molecule antivirals are ready for immediate use, targeting virus families most likely to cause outbreaks, and making effective antivirals accessible worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Portfolio of broad‑spectrum small‑molecule antiviral candidates
A prospective pipeline of orally available small‑molecule antiviral candidates targeted at high‑risk virus families, advanced to varying preclinical and clinical readiness stages.
Small‑molecule antiviral landscape database
A curated database that catalogs small‑molecule antiviral programs (including abandoned assets) with fields for mechanism, class, indications and development stage to inform prioritization and repurposing decisions.
Portfolio of broad‑spectrum small‑molecule antiviral candidates
A prospective pipeline of orally available small‑molecule antiviral candidates targeted at high‑risk virus families, advanced to varying preclinical and clinical readiness stages.
Small‑molecule antiviral landscape database
A curated database that catalogs small‑molecule antiviral programs (including abandoned assets) with fields for mechanism, class, indications and development stage to inform prioritization and repurposing decisions.
Services
Joint programs with academic, industry and government partners to discover, optimize and advance broad‑spectrum small‑molecule antivirals.
Creation and maintenance of a comprehensive small‑molecule antiviral landscape database to support pipeline mapping, gap analysis and prioritization of development opportunities.
Preparation of Phase II/III randomized clinical trial designs and associated readiness activities to enable rapid initiation of efficacy trials during outbreaks.
Advance identification of manufacturing partners and development of manufacturing plans to support rapid scale‑up and distribution of small‑molecule antivirals.
Joint programs with academic, industry and government partners to discover, optimize and advance broad‑spectrum small‑molecule antivirals.
Creation and maintenance of a comprehensive small‑molecule antiviral landscape database to support pipeline mapping, gap analysis and prioritization of development opportunities.
Preparation of Phase II/III randomized clinical trial designs and associated readiness activities to enable rapid initiation of efficacy trials during outbreaks.
Advance identification of manufacturing partners and development of manufacturing plans to support rapid scale‑up and distribution of small‑molecule antivirals.
Expertise Areas
- Antiviral drug discovery
- Broad‑spectrum small‑molecule therapeutics
- Medicinal chemistry and lead optimization
- Virology and viral target biology
Key Technologies
- Small‑molecule therapeutics
- Broad‑spectrum antiviral target strategies
- Medicinal chemistry
- AI and machine‑learning for drug discovery
News & Updates
The world needs U.S. innovation, says READDI board member Barbara Stephenson, UNC-Chapel Hill Vice Provost for Global Affairs and Chief Global Officer and former U.S. Ambassador to Panama.
Dr. Sophie Yacoub discusses the potential for therapeutics against dengue, a rapidly surging mosquito-borne virus in the Americas.
READDI announces a partnership with South Korea’s National Institute of Infectious Diseases, NIH, and KDCA to advance antiviral research.
READDI is involved in building a coalition to accelerate antiviral drug development.
READDI’s approach includes developing drugs for unknown future viruses, emphasizing preparedness.
READDI was awarded a $65 million grant from NIH to establish the AViDD Center at UNC-Chapel Hill.
The world needs U.S. innovation, says READDI board member Barbara Stephenson, UNC-Chapel Hill Vice Provost for Global Affairs and Chief Global Officer and former U.S. Ambassador to Panama.
Dr. Sophie Yacoub discusses the potential for therapeutics against dengue, a rapidly surging mosquito-borne virus in the Americas.
READDI announces a partnership with South Korea’s National Institute of Infectious Diseases, NIH, and KDCA to advance antiviral research.
READDI is involved in building a coalition to accelerate antiviral drug development.
READDI’s approach includes developing drugs for unknown future viruses, emphasizing preparedness.
READDI was awarded a $65 million grant from NIH to establish the AViDD Center at UNC-Chapel Hill.